Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report
Tetz V. Kardava K. Shulenbayev O. Vecherkovskaya M. Khodadadi-Jamayran A. Tsirigos A. Tetz G.
2025Dove Medical Press Ltd
ImmunoTargets and Therapy
2025#141201 - 1207 pp.
Purpose: Prostate cancer is the most common malignancy among older man and often a challenge owing to its rapid spread and age-related comorbidities. SL-28 (Leukocyte-Tells) is a novel cell therapy that uses allogeneic leukocytes whose anticancer activity is altered ex vivo using the recently discovered Universal Receptive System. Patients and Methods: A 79-year-old man with Т2сNOMx1, Gleason 7 (3+4) adenocarcinoma of the prostate, with a total PSA level of 10.6 ng/mL and free PSA:total PSA ratio of 11.4% received hormone therapy. Due to an insufficient clinical response and poor tolerance to the therapy, the patient underwent novel allogeneic SL-28 cell therapy. Results: SL-28 therapy was well-tolerated, with no serious adverse effects. The levels of laboratory markers of prostate cancer, such as prostate-specific antigen, gradually improved from the second week of SL-28 therapy. Complete responses, including the resolution of bone metastasis within 4 months of therapy, were confirmed by computed tomography and histology. Conclusion: SL-28 was efficient and safe approach in a patient with stage IV prostate cancer, supporting its potential in an allogeneic cell therapy for advanced malignancies.
cell therapy , leucocyte-tells , oncology , prostate cancer , SL-28 , teazeled receptors , TezR , Universal receptive system
Text of the article Перейти на текст статьи
Human Microbiology Institute, New York, 10013, NY, United States
Private Hospital International Almaty, Almaty, Kazakhstan
Applied Bioinformatics Laboratories, Division of Advanced Research Technologies, NYU School of Medicine, New York, 10016, NY, United States
Department of Pathology, NYU School of Medicine, New York, 10016, NY, United States
Department of Medicine, Division of Precision Medicine, NYU School of Medicine, New York, 10016, NY, United States
Tetz-Laboratories, New York, 10013, NY, United States
Second Life Therapeutics, New York, 10014, NY, United States
Human Microbiology Institute
Private Hospital International Almaty
Applied Bioinformatics Laboratories
Department of Pathology
Department of Medicine
Tetz-Laboratories
Second Life Therapeutics
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026